Damora Therapeutics, Inc. Common Stock (DMRA) – What Are Researchers Saying About This Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has earned an average recommendation of “Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.50.

A number of equities research analysts have recently weighed in on the company. Guggenheim lifted their price objective on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, September 25th. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of DMRA stock opened at $21.53 on Thursday. The firm has a market cap of $1.33 billion, a PE ratio of -6.39 and a beta of 1.43. The company has a 50-day moving average of $24.86 and a two-hundred day moving average of $25.63. Damora Therapeutics, Inc. Common Stock has a 1-year low of $4.95 and a 1-year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. Sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The shares were purchased at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the purchase, the chief executive officer owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DMRA. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at $303,000. Arizona State Retirement System acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $260,000. Seven Fleet Capital Management LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.